Bristol-Myers Squibb Says Psoriatic Arthritis Medication Sotyktu Received FDA Approval
MT Newswires Live
Yesterday
Bristol-Myers Squibb (BMY) said late Friday its Sotyktu inhibitor has received approval from the US Food and Drug Administration to treat adults with active psoriatic arthritis.
The company said that the approval is based on results from its POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of a 6 mg once-daily dose of Sotyktu in patients with active psoriatic arthritis.
In both trials, treatment with Sotyktu met its primary endpoint and key secondary endpoints, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.